European Multicentre Study in Children Born Small for Gestational Age with Persistent Short Stature: Comparison of Continuous and Discontinuous Growth Hormone Treatment Regimens

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F09%3A5745" target="_blank" >RIV/00216208:11130/09:5745 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/09:5745

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

European Multicentre Study in Children Born Small for Gestational Age with Persistent Short Stature: Comparison of Continuous and Discontinuous Growth Hormone Treatment Regimens

Popis výsledku v původním jazyce

The most effective growth hormone (GH)treatment regimen for increasing height in short children born small for gestational age (SGA) has not been well defined. Methods: Short SGA children (n=151, age 3-8 years, height less than -2.5 standard deviation scores) were randomised to receive low-dose GH for 2 years (0.033/0.033 mg/kg/day, n=51), high-dose GH for 1 year and then no treatment for 1 year (0.100/0 mg/kg/day, n=51) or were untreated for 1 year then received mid-dose GH for 1 year (0/0.067 mg/kg/day, n=47). Height, bone age and adverse events were determined at check-ups every 3 months. Results: The mean +/- SD additional height gain with GH after 1 year, relative to untreated controls, was higher with discontinuous high-dose than with continuouslow-dose GH (6.5 +/- 0.2 vs. 3.3 +/- 0.2 cm). After 2 years, the additional height gain was similar between high- and low-dose GH groups (between-group treatment difference=0.2, 95% CI=-0.8 to 1.2 cm, p=0.702).

Název v anglickém jazyce

European Multicentre Study in Children Born Small for Gestational Age with Persistent Short Stature: Comparison of Continuous and Discontinuous Growth Hormone Treatment Regimens

Popis výsledku anglicky

The most effective growth hormone (GH)treatment regimen for increasing height in short children born small for gestational age (SGA) has not been well defined. Methods: Short SGA children (n=151, age 3-8 years, height less than -2.5 standard deviation scores) were randomised to receive low-dose GH for 2 years (0.033/0.033 mg/kg/day, n=51), high-dose GH for 1 year and then no treatment for 1 year (0.100/0 mg/kg/day, n=51) or were untreated for 1 year then received mid-dose GH for 1 year (0/0.067 mg/kg/day, n=47). Height, bone age and adverse events were determined at check-ups every 3 months. Results: The mean +/- SD additional height gain with GH after 1 year, relative to untreated controls, was higher with discontinuous high-dose than with continuouslow-dose GH (6.5 +/- 0.2 vs. 3.3 +/- 0.2 cm). After 2 years, the additional height gain was similar between high- and low-dose GH groups (between-group treatment difference=0.2, 95% CI=-0.8 to 1.2 cm, p=0.702).

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hormone Research

ISSN

0301-0163

e-ISSN

—

Svazek periodika

71

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

8

Strana od-do

—

Kód UT WoS článku

000262424700008

EID výsledku v databázi Scopus

—